Local and systemic methotrexate in management of caesarean scar pregnancy

Archive ouverte

Toutain, Typhaine | Capmas, Perrine | Fernandez, Hervé | Couet, Déborah | Pourcelot, Anne-Gaëlle | Debras, Elodie

Edité par CCSD ; Elsevier -

International audience. Study objective: The aim is to analyze the management of cesarean scar pregnancy (CSP) based on local and systemic Methotrexate, a protocol implemented in a referral center.Design: This is an observational, retrospective, monocentric, cohort study with a description of the local protocol, treatment results and tolerance profile. Design Classification III.Setting: Tertiary Referral center.Patients: All patients with CSP, confirmed by a reference ultrasound, without severity criteria requiring emergency surgery, between March 2015 to August 2022 were consecutively included.Interventions: All patients were treated by an Echo-guided trans-vaginal aspiration of the gestational sac followed by a local injection of Methotrexate 1 mg/kg under general anesthesia combined with Mifepristone and followed by an injection of 1 mg/kg within 2 days.Measurement and main finding: We included 35 patients with a mean hCG level of 28 872 UI/l ± 38063 UI/l and a mean gestational age of 6.8 ± 1.6 weeks of gestation. All patients were managed effectively with a good reduction in hCG serum levels. The mean duration of hCG negativation was 66 ± 38 days after the start of management. Only one patient who had received the department's Methotrexate protocol required a second line of treatment. Among major complications, 2 patients experienced hemorrhagic shock which resolved without recourse to hemostasis hysterectomy. The success rate defined by the absence of recourse to secondary treatment was therefore 91.4 %. Among minor complications, the main complication was methotrexate-induced hepatic cytolysis in 7 patients (20 %). Nine women (26 %) required secondary hysteroscopic resection of trophoblastic retention. Twenty-one patients (60 %) had an ultrasound diagnosis of caesarean scar defect (CSD) after CSP management.Conclusion: The combination of transvaginal ultrasound-guided local MTX, Mifepristone and systemic MTX appears to be an effective treatment protocol for patients with CSP.

Consulter en ligne

Suggestions

Du même auteur

Asherman Syndrome after Uterine Artery Embolization: A Cohort Study about Surgery Management and Fertility Outcomes

Archive ouverte | Jegaden, Margaux P.O. | CCSD

International audience. Study Objective: To study the severity of intrauterine adhesions (IUA) after uterine arterial embolization and to evaluate fertility, pregnancy, and obstetrical outcomes after hysteroscopic t...

What does non-eligibility for myoma surgery mean in the context of sequential prescription of ulipristal acetate?

Archive ouverte | Pourcelot, Anne-Gaëlle | CCSD

International audience

Surgical removal of essure® micro inserts by vaginal hysterectomy or laparoscopic salpingectomy with cornuectomy: Case series and follow up survey about device-attributed symptoms resolution

Archive ouverte | Jegaden, Margaux | CCSD

International audience. Introduction: Inserts Essure® were used as a definitive sterilization method from 2001 to 2017. They have been used for more than 750,000 procedures. Gynecological or extra gynaecological adv...

Chargement des enrichissements...